In addition, we established BRAFV600E-driven transgenic mouse model of thyroid cancer (TPO-Cre/LSL-BrafCA) as described previously [15], and demonstrated that Ng2 was significantly increased in tumor tissues from BRAF-mutant mice (BRAFV600E) compared with wild-type ones (BRAFWT) by qRT-PCR and immunofluorescence (IF) assays (Fig. 1C, D). This evidence concerns the gene BRAF and thyroid cancer.